Trial site
Haifa
Haifa, 3109601, IsraelNot linked to an institution yet
- 15running trials
- 3closed trials
The trials here
What the 18 trials at this site are about, from their registry records.
- Phase
- Phase 313 trials
- Phase 23 trials
- Phase 2/31 trial
- Status
- Active, not recruiting9 trials
- Recruiting6 trials
- Completed3 trials
- Lead sponsor
- GlaxoSmithKline14 trials
- Tesaro, Inc.3 trials
- ViiV Healthcare1 trial
Running trials
Recruiting
A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
NCT07286331· Phase 3· GlaxoSmithKline· Source
Contact: Emad Matanes (principal investigator)
Recruiting
A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis
NCT07201051· Phase 2· GlaxoSmithKline· Source
Contact: Michal Shteinberg (principal investigator)
Recruiting
Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
NCT06961214· Phase 3· GlaxoSmithKline· Source
Contact: Emilia Hardak (principal investigator)
Recruiting
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588· Phase 3· GlaxoSmithKline· Source
Contact: Salem Billan (principal investigator)
Active, not recruiting
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
NCT05979311· Phase 3· ViiV Healthcare· Source
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717· Phase 2/3· GlaxoSmithKline· Source
Contact: Devy Zisman (principal investigator)
Active, not recruiting
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
NCT05757102· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
NCT04915755· Phase 3· GlaxoSmithKline· Source
Recruiting
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
NCT04641247· Phase 2· GlaxoSmithKline· Source
Contact: Amnon Amit (principal investigator)
Active, not recruiting
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
NCT04484623· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
Linerixibat Long-term Safety, and Tolerability Study
NCT04167358· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
NCT03981796· Phase 3· Tesaro, Inc.· Source
Active, not recruiting
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
NCT03602859· Phase 3· Tesaro, Inc.· Source
Active, not recruiting
Extended Access of Momelotinib in Adults With Myelofibrosis
NCT03441113· Phase 2· GlaxoSmithKline· Source
Active, not recruiting
A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
NCT02655016· Phase 3· Tesaro, Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error